Medtronic plc


SKU: MDT-1 Category:


Medtronic plc delivered an all-around beat in the previous quarter, delivering mid-single-digit revenue growth across diverse business segments and global regions. Cardiovascular, Neuroscience, and Medical Surgical sectors all contributed to this growth, with Diabetes witnessing an acceleration to high single-digit growth. Simultaneously, Medtronic continued its comprehensive transformation, enhancing global operations, quality, and supply chain. Medtronic’s AiBLE ecosystem in Cranial and spinal Technologies and advancements in surgical franchises contributed to their leadership positions. Synergistic businesses, encompassing Aortic, Coronary, Cardiac Surgery, and Endoscopy, achieved mid-single-digit growth, with standout performances in various segments. Medtronic’s highest growth markets, including Cardiac Ablation Solutions and Structural Heart, demonstrated promising trajectories driven by innovations in pulse-field ablation catheters and superior valve performance in TAVR. In Neurovascular, high single-digit growth was achieved globally, excluding China, while Robotic Surgical Technologies, featuring the Hugo Robotic system, expanded its international presence. The Diabetes sector experienced significant growth, marked by the successful launch of the MiniMed 780G system, contributing to the highest growth in a decade. The company also received US FDA approval for the Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure. Upon receiving this approval, Medtronic will promptly commence commercialization.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!